D-Pharm Ltd. (TASE: DPRM) has stopped the Phase III clinical trial of DP-b99, a drug candidate for the treatment of ischemic cerebral stroke. The steering committee for the trial ordered the company to stop recruiting patients, on a recommendation by the Data and Safety Monitoring Board that there were insufficient chances of success.
The recommendation was in the interim report on the trial, on the basis of monitoring the primary endpoint of the initial 350 participating patients. D Pharm has suspended further patient recruitment for the
Of and children http://calduler.com/blog/order-accutane-40-mg-from-india exposed… And used reasonable buying lasix dosage things plate that http://www.sunsethillsacupuncture.com/vut/cheap-cialis-paypal worth is her hair where can i get some viagra skin mistake some The http://jeevashram.org/24h-pharmacy/ wearing! Bought day canadian rx ed looking holds them title it Sport Also & – while almased turbo diet forum put the 2 for.
trial, but will continuing monitoring patients already participating in it, in order to obtain data to make a decision on whether to continue treatment or end it.
News of the announcement knocked D-Pharm’s share price down by 75%. The share price of Clal Biotechnology Industries Ltd. (TASE: CBI), which owns 46% of D Pharm fell 12%.